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Abstract. Follistatin (FST), as a single-chain glycosylated
protein, has two major isoforms, FST288 and FST315. The
FST315 isoform is the predominant form whilst the FST288
variant accounts for less than 5% of the encoded mRNA.
FST is differentially expressed in human tissues and aberrant
expression has been observed in a variety of solid tumours,
including gonadal, gastric and lung cancer, hepatocellular
carcinoma, basal cell carcinoma and melanoma. Based on
the current evidence, FST is an antagonist of transforming
growth factor beta family members, such as activin and bone
morphogenetic proteins (BMPs). FST plays a role in
tumourigenesis, metastasis and angiogenesis of solid
tumours through its interaction with activin and BMPs, thus
resulting in pathophysiological function. In terms of
diagnosis, prognosis and therapy FST has shown strong
promise. Through a better understanding of its biological
functions, potential clinical applications may yet emerge. 
Follistatin (FST), which was first isolated from porcine and
bovine follicular fluid (1, 2), was initially described as a
protein involved in the regulation of the secretion of follicle-
stimulating hormone. This monomeric glycosylated
polypeptide chain is encoded by a single gene located on the
long arm chromosome 5q11.2 (3), which through alternative
splicing may be transcribed into the mRNA precursors,
FST317 and FST344. From these precursors, three major
FST isoforms may be produced, namely FST288 (from pre-
FST317), FST315 (from pre-FST344) and a third FST
isoform, FST303, produced from the post-translational
truncation of the FST315 C-terminus. These three main FST
isoforms can also be glycosylated to yield six further FST
isoforms that were previously identified in bovine (4) and
porcine (5, 6) follicular fluid. At the core, all FST isoforms
contain a 63 residue N-terminal domain and three follistatin
domains, termed FSD1, FSD2 and FSD3. These domains
comprise 73-77 amino acid residues and are characterised by
an arrangement of 10 conserved cysteine residues (7). Both
FST288 and FST315 are differentially expressed in human
tissues (6-9). FST315 is the predominant isoform, whilst the
FST288 isoform accounts for less than 5% of the encoded
mRNA (10, 11). Some molecules such as activin,
transforming growth factor beta (TGFβ), forkhead domain
transcription factor L2 (12, 13), gonadotropin-releasing
hormone (14), zinc finger protein (GLI2) (15),
dexamethasone (16), androgens (17), activators of wingless-
related integration site (WNT) signalling (18, 19) and 1,25-
dihydroxyvitamin D (20) have been shown to regulate the
transcription of the FST gene. In addition, down-regulation
of FST gene expression by peroxisome proliferator-activated
receptor gamma (PPARγ) or the transcription factor
epiprofin (21, 22) has been shown.
As an antagonist of TGFβ superfamily member activin,
FST seems to primarily function in relation to the role that
activin plays. Along with FST, activin acts as a pleiotropic
growth factor system, which is involved in proliferation,
differentiation, and apoptosis of a number of cell types (23-
28). As such, the functions of the FST isoforms are therefore
linked to their binding affinity for activin (6, 10, 11, 29-37).
In fact, this critical binding and neutralisation of activin,
either partial or complete, is based on the order of at least
two of the FST cysteine domains and its N-terminal (38),
conferring a difference in affinities for activin between the
FST isoforms. The binding complex between activin and
FST generally occurs in a 1:2 ratio, where the two FST
molecules, connected C-terminus to N-terminus, envelop the
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activin molecule, thus blocking access to both the type I and
type II receptor binding sites (9). The binding complex
handicaps the interaction of activin with its specific
receptors, leading to the inhibition of most of its the
biological effects in various cells and tissues (5, 6, 11, 32,
35). An important contribution of the FSD1 region to FST
localisation and hence, bioactivity, lies in its ability to bind
to plasma membrane heparin sulfate proteoglycans. For
example, FST288 binds to heparin sulfate proteoglycans with
a high affinity and may function as a local regulator by
potentially preventing the autocrine, endocrine and paracrine
actions of activin (39). Additionally, FST288-activin binding
complex can interact with cell-surface proteoglycans
followed by the internalization and subsequent degradation
of this complex with lysosomal enzymes (3, 5, 6).
Conversely, FST315 is predominantly localised in the
circulation, consistent with its low binding affinity for
heparin, and its binding to activin appears to be irreversible
(5). 
Activin seems to be able to exert context-dependent and
cell type-specific inhibiting and activating functions (40).
There is evidence that activin can both have an inhibitory
or proliferative effect on cell proliferation; dependent on
the cell type (41-47). In vivo studies have shown that FST
knockout mice died soon after birth due to a variety of
skeletal and cutaneous defects amongst other defects seen
in the activin-deficient mice (48). Lin et al. also
demonstrated that mice with an FST315-expressing
construct could overcome this neonatal lethality but still
had severe biological defectsii. Overexpression of mouse
FST using the mouse metallothionein I promoter in
transgenic mice led to gonadal defects and eventual
infertility, primarily due to local effects of FST in these
tissues (50). Dermatological defects were present in both
FST-knockout and -overexpressing mice, but there was no
evidence of cancer (51). Some of these defects were
similar to those that were seen in bone morphogenetic
protein 5 (Bmp5)-mutant mice (52) and TGFβ-
overexpressing mice (53). These similarities suggested that
FST might be a modulator of other TGFβ-related proteins
apart from activin or might function independently (48).
Some other studies have demonstrated that FST may also
bind to other molecules such as BMPs, especially BMP-2,
-4, -5, -6, -7 and -11 (4, 54-58), myostatin (59) and TGFß3
(60). Table I shows the expression profile of FST and its
targeting ligands in various tissues and organs of the
human body. In addition, FST may also have an interaction
with other non-TGFβ family proteins, such as angiogenin,
known as a pro-angiogenic factor (61), and α2-
macroglobulin, known as a serum pan-protease inhibitor
(62). However, further investigations are required to
explain the functional value of the interplay between FST
and these molecules.
Follistatin in the Development and 
Progression of Solid Tumours
A study on the molecular mechanisms underlying antral
gastric tumours, which develop in gastrin-deficient mice,
demonstrated elevated FST expression in the proliferative
neck zone of hyperplastic antrum, a trend which has also
been observed in human gastric cancer (63). These findings
indicated that antral hyperplasia in gastrin-deficient mice
involves amplification of mucous cell lineages, in which FST
may play a role. In addition, strong FST expression was
found in basal cell carcinoma and seemed to be mainly
activated by transcription factor GLI2, which, as a Hedgehog
signalling mediator, has been shown to be up-regulated by
the expression of FST (15, 64). This phenomenon is
suggestive of the engagement of FST in the development of
basal cell carcinoma, which has yet to be fully elucidated. 
Stove et al. found that all melanoma cell lines expressed
activin receptors. Treatment of these cell lines with activin
also resulted in the phosphorylation of SMAD signal
transduction molecules (65). Secretion of FST, either native
or after retroviral transduction, efficiently prevented SMAD
activation or activation of an activin-responsive luciferase
reporter construct. In melanocytes, activin treatment led to
growth inhibition and induction of apoptosis, processes
which were counteracted by an addition of FST. Thus this
study suggests that in melanoma, FST is involved in
neutralising the effects of activin.
Activin also appears to be a major regulatory factor in
liver tissue homeostasis, controlling cell proliferation and
apoptosis. Both activin and TGFβ itself may inhibit DNA
synthesis and induce apoptosis in vitro as well as in vivo (66-
72). It has been reported that experimentally administered
FST acted as an inducer of hepatocellular DNA synthesis
(73-76) through reduction in the local bioavailability of
activin. Additionally, overexpression of FST was also found
in rodent liver tumours (77), of which most were
hepatocellular carcinomas, when compared to surrounding
liver tissue; the level of overexpression of FST was different
but independent of the carcinogen treatment that rodents had
received and the histological stage of malignancy.
Differential expression of FST and its interacting ligands is
shown in Table II.
In addition, there is also some indirect proof regarding the
growth-promoting effect of FST on prostate cancer cells.
Rapamycin (78) and soy isoflavones (79), plant-derived
polyphenolic compounds with estrogen-like properties,
inhibit prostate cancer cell growth and are associated with a
decrease in the expression of FST. Type III TGFβ receptor
has been reported to play an inhibitory role in the growth of
prostate cancer cells (80). FST has been shown to directly
bind to and completely block type III TGFβ receptor-induced
epithelial–mesenchymal transition of normal murine
CANCER GENOMICS & PROTEOMICS 13: xxx-xxx (2016)
2
mammary gland epithelial cell line in vitro (60) and thus
might promote prostate cell proliferation by targeting this
receptor. 
It was found that exogenously added activin A and B
induced an inhibitory effect on the growth of two human
prostate cancer cell lines, LNCaP and DU145, which was
completely reversed by FST (24). Overexpression of FST
was observed in human LNCaP cells (81), which is in line
with the theory of FST overproduction favouring the growth
of prostate cancer by inhibiting signalling of activin (23).
However, another human prostate cancer cell line, PC3, is
resistant to the growth-inhibiting effects of activin A.
Intriguingly, this phenomenon is further explained by the
study of McPherson et al. which showed that only PC3 cells
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Table I. Expression profile of follistatin (FST) and its target molecules in different organs and tissues.  
Tissue                             FST      INHA     INHBA    INHBB      BMP2      BMP4      BMP5        BMP6       BMP7      BMP11     Myostatin     TGFβ3
Adipose tissue                   0             0               0               0              0              77              0                0               0                 0                 0               77
Adrenal gland                 30             0               0             30              0                0              0                0               0               30                 0                 0
Ascites                               0             0               0               0              0                0              0                0               0                 0                 0                 0
Bladder                              0             0               0               0              0                0              0                0               0                 0                 0                 0
Blood                                 0             0             24               0              0                0              0              98               0               16                 0                 0
Bone                                83             0             55               0            27              97              0                0             13               55                 0               41
Bone marrow                  41             0             20               0              0                0              0                0               0                 0                 0               41
Brain                                  2             9               2               5              4                7              2                8             43               23                 1               13
Cervix                                0             0               0               0          247                0              0              61               0                 0                 0                 0
Connective tissue            87             0             26               0            26              13            13                6             33               13                 6               20
Ear                                 248             0               0               0              0                0              0                0               0                 0                 0                 0
Embryonic tissue            42             0             42               0            14            108            37                9             32                 9                 0               14
Oesophagus                       0             0             49               0              0                0              0                0               0                 0                 0               49
Eye                                  47           19             47             33            43              43              9              14             86             129                 4               33
Heart                                11             0               0             22            44              11          100                0           100               22                11               78
Intestine                           12             0             38               8            17            219              4              21             30               25                 0                 8
Kidney                             14             0               4               4              4                4              0                9             42                 4                 0               18
Larynx                           127             0             85               0          426                0              0              42               0                 0                 0                 0
Liver                                24             9               4               9              9              63              9                0               0               14                 0                 9
Lung                                41             2             23             20            29              14            11              20               5               11                11               23
Lymph                               0             0               0               0              0              22              0                0             90                 0                 0                 0
Lymph node                      0             0               0               0              0              11              0                0             44               11                 0                 0
Mammary gland              26             0             19             26              6              26            72                6             39               33                 0               26
Mouth                              15             0             30               0              0              60              0              15             15               45                 0               30
Muscle                               0             0             18               0              0                0            28                0               9               18                 9                 0
Nerve                               64             0               0             64              0                0              0                0               0             128                 0               64
Ovary                             325           49               9               0              0              29              9              78             39                 0                 0               29
Pancreas                          32             0             37               4            14                4            32                0               4               14                 0               51
Parathyroid                        0             0               0               0              0                0              0              48               0               48                 0                 0
Pharynx                             0             0               0               0              0                0              0                0               0                 0                 0                 0
Pituitary gland                  0             0               0               0              0                0              0                0               0                 0                 0                 0
Placenta                             3           49             88               0            21              63            74              35             67                 7                 3               52
Prostate                            42             0               0             10              5              21            10              15             36               10                 0               63
Salivary gland                   0             0               0               0              0              49              0                0               0                 0                 0                 0
Skin                                   4             0             61               9              0                4              0                0               9               37                 0                 0
Spleen                              37             0               0               0            37                0              0                0               0                 0                 0                 0
Stomach                             0             0             62               0            31            125              0                0             10                 0                 0               10
Testis                                 4           22               0             20              4                6              2                6             34                 6                 0                 4
Thymus                             0             0               0               0              0                0            25                0             37               12                 0                 0
Thyroid                            21           21               0             64              0                0              0                0               0                 0                 0                 0
Tonsil                                 0             0               0               0              0                0              0                0             58               58                 0                 0
Trachea                              0             0               0               0              0                0            57                0             19                 0                 0                 0
Umbilical cord                  0             0               0               0              0                0              0              72               0               72                 0                 0
Uterus                                4             4               8               4              4                0            17                8             12               17                 0               25
Vascular                             0             0           290               0              0              19              0            135               0                 0                 0                 0
INHA/BA/BB: Inhibin alpha/beta a/beta b subunit; BMP2/4/5/6/7/11: bone morphogenic protein 2/4/5/6/7/11: TGFβ3: transforming growth factor
beta 3. Numbers of gene transcripts are transcripts per million which were collected from Unigene (https://www.ncbi.nlm.nih.gov/unigene).
produced the FST288 isoform, while LNCaP and DU145
cells predominantly produced the FST315 isoform. Blockade
of FST288 activity with a neutralizing antibody rendered
PC3 cells responsive to activin A, as measured by inhibition
of proliferation (25). These results indicate that the resistance
of PC3 cells to activin A is more likely due to predominantly
expression of FST288 in comparison with LNCaP and
DU145 cells. Sidis et al. found that inhibition of endogenous
activin bioactivity, irrespective of the FST isoforms being
administered endogenously or exogenously, was correlated
closely with its surface-binding activity (36). These findings
suggest that the cell-surface dwelling FST288 isoform
inhibits activin-mediated downstream signal transduction
pathways more efficiently than does the FST315 isoform.
Further investigations will shed light on the interaction of
the FST288 isoform with activin receptors and, consequently,
the biological effects induced by these molecules. 
In some cases, however, FST may also inhibit tumour
growth. An in vitro study showed that the growth of inhibin-
deficient gonadal tumour cells from mice could be stimulated
in culture via an autocrine mechanism of activin, while FST
added to the culture medium slowed the growth rate of the
tumour cells (82). Another in vitro study observed that for
four ovarian cell lines not synthesizing FST, treatment with
activin (1-100 ng/ml) resulted in an increase of proliferation,
whereas FST treatment (1-100 ng/ml) inhibited their
proliferation (83). This inhibitory function was further
verified in an in vivo study, showing inhibin-deficient mice
that carry the mouse metallothionein I follistatin transgene
exhibited a less severe activin-mediated cancer cachexia-like
wasting syndrome, lower serum activin levels, and a
statistically significant prolonged survival in a number of
cases compared with the mice deficient in inhibin alone (51).
Follistatin in Tumour-associated Angiogenesis
The effect of FST on tumour angiogenesis was found in a study
by Ogino et al. (84), in which two human small cell lung
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Table II. Expression of follistatin (FST) and its target genes in malignancies. 
Tissue                             FST      INHA     INHBA    INHBB      BMP2      BMP4      BMP5        BMP6       BMP7      BMP11     Myostatin     TGFβ3
Adrenal tumor                   0↓↓        0               0             79↑↑          0                0              0                0               0               79↑↑             0                 0
Bladder carcinoma            0             0               0               0              0                0              0                0               0                 0                 0                 0
Breast tumor                   42↑↑        0             21             32↑            0↓↓         42↑↑      118↑↑           0↓↓         42               53↑↑             0               42↑↑
Cervical tumor                  0             0               0               0          347↑↑           0              0              86↑             0                 0                 0                 0
Chondrosarcoma           132             0             48               0            24              48              0              12             12               72                 0               48
Colorectal tumor               0↓↓        0             17               8            17            328              0              26             35               26                 0                 8
Esophageal tumor             0             0             57               0              0                0              0                0               0                 0                 0               57
Gastrointestinal tumor    25↑↑        0             25↓↓          0            16↓↓       202↑↑          0                0               8↓              0                 0                 8↓
Germ cell tumor             37           26               0             11              0                7              7              18             91               41                 0                 3
Glioma                               9             0               0               0            46                9              0                0             74               46                 0                 0
Head and neck tumor     29             7             29             14            74              37              0              14               7               22                 0                 7
Kidney tumor                  14             0               0↓↓          0↓↓          0↓↓           0↓↓          0                0↓↓         87↑↑          14↑↑             0               14↓
Leukemia                        21↑          0               0               0            10                0              0            116               0               21                 0               10
Liver tumor                     20           10             10             10            10            104              0                0               0               31                 0                 0
Lung tumor                     68↑↑        0↓↓          0↓↓          0↓↓          0↓↓         19↑            0↓↓           0↓↓           0↓↓          19↑               0↓↓            9↓↓
Lymphoma                        0             0               0               0              0              27              0                0           207                 0                 0                 0
Non-neoplasia                 10             0             31               0              0              10              0              10             31                 0                 0                 0
Normal                            22           12             24               6            14              21            19              11             33               21                 2               26
Ovarian tumor               393↑        13↓↓          0↓↓          0              0              39↑          13↑            91↑           52↑              0                 0               13↓↓
Pancreatic tumor             66↑↑        0             76↑↑          9↑↑          0↓↓           9↑↑       19                0               9↑↑            9↓↓             0               47↓
Primitive neuro-
ectodermal tumor            0             7               0               0              0              31              0                0             70                 0                 0                 0
Prostate cancer                48↑          0               0               0↓↓          0↓↓         28↑            0              19↑             0↓↓          19↑↑             0               28↓↓
Retinoblastoma                 0             0               0             43              0                0              0                0               0               64                 0                 0
Skin tumor                        0             0             55               0              0                0              0                0             15               23                 0                 0
Soft tissue/muscle 
tissue tumor                   31             0               7               0              7                0            39                0             39               23               15                 0
Uterine tumor                  11↑↑        0↓↓        22↑↑        11↑↑          0↓↓           0              0↓↓           0↓↓         33↑↑          33↑↑             0               22↓
INHA/BA/BB: Inhibin alpha/beta a/beta b subunit; BMP2/4/5/6/7/11: bone morphogenic protein 2/4/5/6/7/11; TGFβ3: transforming growth factor
beta 3. Note: In comparison with corresponding normal control, ↑↑ represents an increase greater than 50%, while ↑ stands for a difference of less
than 50%; ↓↓ represents a decrease greater than 50%, while ↓stands for a reduction of less than 50%. Numbers of gene transcripts are transcripts
per million which were collected from Unigene (https://www.ncbi.nlm.nih.gov/unigene).
cancer cell lines, SBC-3 and SBC-5, were transfected with the
FST gene and subsequently inoculated into the natural killer
cell-depleted severe combined immunodeficient (SCID) mice.
Histological analysis results revealed that the number of
proliferating tumour cells and the tumour-associated
microvessel density were significantly reduced in the lesions
produced by FST transfectants, compared with the parental
SBC-5 or mock control, which was consistent with the results
seen in liver-metastatic lesions produced by FST transfectants.
These observations in both lung- and liver-derived tumours is
suggestive of FST inhibiting tumour angiogenesis. However,
no obvious effect on cell proliferation, motility, invasion, or
adhesion were observed for FST in endothelial cells in vitro
nor on tumour growth and metastasis in vivo (84).
Unlike the findings by Ogino et al. (84), there is also some
evidence indicating that FST may play a promotory role in
the progression of tumour angiogenesis. Kozian et al. found
that FST implantation in the cornea in combination with
subcritical concentrations of fibroblast growth factor (bFGF)
induced a strong angiogenic response (85), which
demonstrates that FST by itself, but particularly in synergy
with bFGF, induces angiogenesis. This may be primarily due
to the action of FST antagonizing activin, which inhibits
bFGF-induced sprouting angiogenesis in vitro and in vivo
(40). Other evidence that FST may have a promotory effect
on tumour angiogenesis is the study by Krneta et al. in which
SCID mice were inoculated with R30C mammary carcinoma
cells transfected with FST288 or activin. The FST-expressing
tumours had a denser network of small-diameter capillaries
than activin-expressing tumours (40). FST288 may be
required for the promotion of angiogenesis in a mouse model
(49). Collectively, FST, especially the FST288 isoform, seems
to be involved in tumour angiogenesis, at least partially
through attenuating activin signalling. 
Follistatin in Solid Tumour Metastasis
In the study by Ogino et al., FST transfectants produced
significantly fewer metastatic colonies in multiple organs,
including lung, liver, and bone in natural killer cell-depleted
SCID mice when compared with their parental cells or vector
control clones (84), supporting the potential role of FST in
controlling tumour metastasis.
BMP2, -4 and -7, together with their inhibitors, including
FST, have been shown to be involved in osteoblastogenesis
(86-88). The activin/FST system was reported to play a
regulatory role in normal bone homeostasis (89-92). It has
been speculated that FST might play a role in the pathogenesis
of bone metastasis through interaction with BMPs and activin. 
A study demonstrated that ribozyme transgene targeting
BMP7 expression in the PC3 prostate cancer cell line
resulted in increased invasiveness and motility, which
appeared to be facilitated by changes in the level of the BMP
antagonists noggin and FST (58). Although these findings
indicate the role of FST in solid tumours, more evidence is
needed for greater clarification of its involvement in the
metastases associated with solid tumours. 
Value of Follistatin in Diagnosis, Prognosis 
and of Solid Tumours
FST is expressed in multiple tissues (10, 77, 93-97), and its
expression levels are altered in tumour tissues (25, 90, 98-
100) and in body fluids (101-104) of patients with solid
tumours. These findings provoked studies investigating FST
as a diagnostic or prognostic marker for solid tumours. One
study showed that serum FST and ovarian carcinoma antigen
CA125 levels were significantly increased in patients with
ovarian cancer when compared with healthy individuals and
patients with benign ovarian cysts, which suggests that the
serum FST level has potential diagnostic value, especially
when combined with CA125 detection in order to reduce the
number of false-positive results (105). Serum levels of FST
were also found to be elevated in patients with hepatocellular
cancer (HCC) (21, 106). Survival of patients with HCC with
high FST levels was significantly shorter than for those with
low serum levels of FST (106). Multivariate analysis
revealed that in addition to large tumour size and presence
of portal vein thrombus, high FST levels were independently
correlated with poor prognosis (106). Therefore, a promising
potential is indicated for FST in HCC prognosis. A survival
analysis of FST in breast, lung, ovarian and gastric cancer
was also performed using an online Kaplan–Meier analysis
(http://kmplot.com/analysis/) (Figure 1) (107). An increased
expression of FST was associated with poorer overall
survival of patients with ovarian, gastric and lung cancer.
These data also correlate with the previously mentioned
studies of serum level in ovarian cancer and HCC. In
contrast, a reduced expression of FST was correlated with
shorter relapse-free survival (Figure 1B), although no
correlation was seen between FST expression and overall
survival of patients with breast cancer (data not shown). 
Blank et al. reported FST in serum was negatively
correlated and was decreased in both distant and lymph node
metastasis associated with gastric cancer compared to patients
without metastasis. In contrast, they noted that tissue from
these patients with metastasis exhibited higher FST levels.
Additionally, neoadjuvantly treated patients with lymph node
metastasis still exhibited lower FST levels, whilst those with
distant metastasis and poorly differentiated tumors (G3/4)
exhibited elevated FST serum levels. Prognostically, a tumour
tissue level of FST below the median was associated with
better survival. However, in primary resected and
neoadjuvantly treated patients, FST levels in tissue had no
impact (108). Therefore FST levels appear to have a further
prognostic significance in gastric cancer.
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Figure 1. Expression of follistatin (FST) is associated with survival of patients with cancer. The association with survival of patients with ovarian,
breast, lung and gastric cancer was analysed in a combined cohort of these cancer types using an online Kaplan–Meier survival analysis tool
(KMplot, http://kmplot.com/analysis/) (107). A: High expression of FST was found to be associated with shorter overall survival (OS) of patients
with ovarian cancer. B: High FST expression was associated with relapse-free survival (RFS) of patients with breast cancer. C: High expression of
FST was associated with shorter OS of patients with lung cancer. D: High FST expression was associated with shorter OS of patients with gastric
cancer. Number of patients of each cohort are provided in Table III. The cut-off levels were auto-selected using the KMplot and number of patients
in each group are listed in Table III. 
Table III. Number of patients and cut-off levels of follistatin (FST) for the Kaplan–Meier survival analyses. 
Cancer type (survival)                     Low FST expression                             High FST expression                                           Cut-off level 
                                                             (no. of patients)                                      (no. of patients)                              (normalised FST expression level)
Ovarian (OS)                                                  222                                                          358                                                                101
Breast (RFS)                                                   792                                                          868                                                                238
Lung (OS)                                                      829                                                          316                                                                456
Gastric (OS)                                                   346                                                          285                                                                  94
OS: Overall survival; RFS: relapse-free survival. The association with survival of patients with ovarian, breast, lung and gastric cancer was analysed
in a combined cohort of these cancer types using an online Kaplan–Meier survival analysis tool (KMplot, http://kmplot.com/analysis/) (107).
Numbers of patients of each cohort and the cut-off levels which were auto-selected using the KMplot are shown.
Other than the potential from diagnostic and prognostic
perspectives, FST might also be considered as a therapeutic
target. Grusch et al. reported that FST was overexpressed
while both activin subunits were down-regulated in the
majority of rat and human liver tumours studied (109).
Treatment of normal and pre-neoplastic hepatocytes with
FST stimulated DNA synthesis preferentially in pre-
neoplastic rat hepatocytes, whereas activin A repressed it.
This study suggests that the balanced expression of FST and
activin becomes deregulated during hepatocarcinogenesis
and the sensitivity of pre-neoplastichepatocytes to activin
signals suggests the activin/FST system might be a
promising target for therapeutic intervention.
FST was indicated to have potential in clinical use (81,
104) in prostate cancer, but its diagnostic effectiveness was
found not to be significantly superior to that of activin A or
prostate-specific antigen (110), although it could still be
useful as a biomarker for follow-up of patients with prostate
cancer undergoing antimetastatic treatments. Together with
another possibility that FST may contribute to fostering bone
metastasis formation in patients with prostate cancer (58, 86-
88, 111), FST may be regarded as a potential, molecular
target in the treatment of metastatic bone disease.
Conclusion
Based on current findings, FST plays a role in
tumourigenesis, progression, metastasis and angiogenesis of
solid tumours. This molecule seems to exert its effect mainly
by interaction with TGFβ family members, such as activin
and BMPs. As an antagonist of activin, FST seems primarily
to function depending on the role that activin plays, exerting
context-dependent and cell type-specific inhibition and
activation (40), including activion of the FST-stimulating
effect on gastric (63, 112) and prostate (23-25, 36, 81)
cancer, while playing an inhibitory role in gonadal tumours
(81, 82). FST288 has more inhibitory effects on activin-
induced biological action than FST315, which has been
supported by a series of studies (23-25, 36, 81). Future
investigations can elucidate the exact role played by the
FST288 isoform in solid tumours and also the corresponding
application in diagnosis and treatment.
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